Pet dogs spontaneously develop lymphoma. An anthracycline-based multidrug chemotherapy regimen represents the treatment cornerstone; however, cure is rarely achieved. We have been treating dogs with B-cell lymphoma with an autologous vaccine (APAVAC®) and CHOP-based chemotherapy since 2011.
Opportunities and challenges of active immunotherapy in dogs with B-cell lymphoma: a 5-year experience in two veterinary oncology centers / Marconato, Laura; Aresu, Luca; Stefanello, Damiano; Comazzi, Stefano; Martini, Valeria; Ferrari, Roberta; Riondato, Fulvio; Rouquet, Nicole; Frayssinet, Patrick; Sabattini, Silvia. - In: JOURNAL FOR IMMUNOTHERAPY OF CANCER. - ISSN 2051-1426. - ELETTRONICO. - 7:1(2019), pp. 146.1-146.9. [10.1186/s40425-019-0624-y]
Opportunities and challenges of active immunotherapy in dogs with B-cell lymphoma: a 5-year experience in two veterinary oncology centers
Marconato, Laura;Stefanello, Damiano;Sabattini, Silvia
2019
Abstract
Pet dogs spontaneously develop lymphoma. An anthracycline-based multidrug chemotherapy regimen represents the treatment cornerstone; however, cure is rarely achieved. We have been treating dogs with B-cell lymphoma with an autologous vaccine (APAVAC®) and CHOP-based chemotherapy since 2011.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
